| __timestamp | Amicus Therapeutics, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 7459000 |
| Thursday, January 1, 2015 | 76943000 | 11831000 |
| Friday, January 1, 2016 | 104793000 | 25705000 |
| Sunday, January 1, 2017 | 149310000 | 46181000 |
| Monday, January 1, 2018 | 270902000 | 59497000 |
| Tuesday, January 1, 2019 | 286378000 | 65003000 |
| Wednesday, January 1, 2020 | 308443000 | 74506000 |
| Friday, January 1, 2021 | 272049000 | 126006000 |
| Saturday, January 1, 2022 | 276677000 | 126215000 |
| Sunday, January 1, 2023 | 152381000 | 120161000 |
Cracking the code
In the ever-evolving world of biotechnology, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Amicus Therapeutics consistently outpaced Protagonist in R&D spending, peaking in 2020 with a 547% increase from 2014. However, 2023 saw a notable decline, with expenses dropping by nearly 45% from their 2020 high. In contrast, Protagonist Therapeutics exhibited a steady upward trend, culminating in a 1,510% increase over the same period.
These trends reflect strategic shifts and market dynamics, offering insights into each company's innovation strategy and potential future breakthroughs.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Amicus Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE